Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.
Meet Ami Gopalan, who shares her journey living with IgA nephropathy, a rare autoimmune kidney disease that attacks the kidneys.
Meet Nathan Mermilliod who shares his experience living with severe hemophilia B, a rare bleeding disorder that requires lifelong prophylactic treatment to prevent dangerous internal bleeds.
Meet Kevin Wake, a 57-year-old sickle cell warrior from Kansas City, who shares his personal journey living with this lifelong genetic blood disorder.
In this emotional video, meet Kate Vander Weele who shares her family’s journey as her 12-year-old son Logan battles Duchenne muscular dystrophy, a rare and fatal genetic disease that causes progressive muscle loss.
On Sunday, November 9, Senate Majority Leader Thune announced that he had reached an agreement with a group of 8 Democratic senators and the White House on a deal to end the longest shutdown in U.S. history. On Monday, November 10, the Senate approved the government funding bill by a vote of 60-40, which sends the legislative package back to the House of Representatives.
To discuss navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer (mBC), AMCP Market Insights virtually convened an expert panel of managed care stakeholders in February 2025.
To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.
President Donald Trump announced a series of agreements with Eli Lilly and Company and Novo Nordisk to offer Most-Favored-Nation (MFN) prices on two GLP-1 therapies, semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). This marks the fourth and fifth publicly announced agreements between the Trump administration and pharmaceutical manufacturers, joining earlier announcements with Pfizer, AstraZeneca, and EMD Serono. The manufacturers also agreed to cap prices for insulin products and other commonly prescribed diabetes medications.
Read the Journal of Managed Care + Specialty Pharmacy (JMCP) - November 2025 Issue
